Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1987 Aug 1;166(2):303–318. doi: 10.1084/jem.166.2.303

Characterization of cells from invaded lymph nodes in patients with solid tumors. Lymphokine requirement for tumor-specific lymphoproliferative response

PMCID: PMC2189587  PMID: 2955070

Abstract

The specific immune response against the malignant cells was investigated in patients with urinary bladder or larynx cancer. Lymphocytes from lymph nodes that drain the tumor site were tested for their proliferative and cytotoxic capacities against autologous malignant cells isolated from the primary tumor. In no occasion was a proliferative or a cytotoxic response observed. However, when the lymph node cell suspensions were depleted of cells expressing both OKM1 and Leu-7 markers by rosetting with the appropriate mAbs, a proliferative response could be observed. The lymphocytes responded to autologous tumor cells only if IL-2 was added to the cultures. IL-2 alone induced some cell proliferation, which was not, however, comparable to that observed in response to both IL-2 and tumor cells. A panel of allogeneic tumor cells consistently failed to stimulate OKM1-, Leu-7- cells in vitro. Response to autologous tumor cells was not caused by HLA-encoded molecules, as occurs in the autologous mixed lymphocyte reaction, since OKM1-, Leu-7- cells failed to be stimulated by autologous non-T cells. A proliferative response was observed only with cells from lymph nodes that had been classified as invaded by malignant cells according to histopathologic criteria. Cells from noninvaded lymph nodes consistently failed to respond. Cells stimulated with autologous tumor cells could be expanded in short-term lines by continuous addition of IL-2 and malignant cells. One of these lines, which comprised mainly T8+ cells, was stimulated to proliferate only by autologous tumor cells, and its proliferative response was inhibitable by anti-class I and not by anti-class II mAbs. This line showed lytic capacities against autologous malignant targets, while it was inefficient against all of the other allogeneic cells tested. In another set of experiments, the mechanisms whereby exogenous IL-2 had to be added to the cultures to sustain a proliferative response against neoplastic cells were investigated. When cocultured with autologous malignant cells, OKM1-, Leu-7- lymphocytes expressed IL-2 receptors, as could be assessed by anti-Tac fluorescent staining. Under these culture conditions, these cells did not produce IL-2, and no proliferation was observed. Addition of purified IL-1 to the cultures induced IL-2 production and cell proliferation. It is concluded that metastatic lymph nodes contain a T cell population that can be detected in a proliferative assay when both suppressor cells are removed and the appropriate molecular signals are supplied.

Full Text

The Full Text of this article is available as a PDF (1,022.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abo T., Balch C. M. A differentiation antigen of human NK and K cells identified by a monoclonal antibody (HNK-1). J Immunol. 1981 Sep;127(3):1024–1029. [PubMed] [Google Scholar]
  2. Abo T., Cooper M. D., Balch C. M. Postnatal expansion of the natural killer and keller cell population in humans identified by the monoclonal HNK-1 antibody. J Exp Med. 1982 Jan 1;155(1):321–326. doi: 10.1084/jem.155.1.321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Albert F., Buferne M., Boyer C., Schmitt-Verhulst A. M. Interactions between MHC-encoded products and cloned T-cells. I. Fine specificity of induction of proliferation and lysis. Immunogenetics. 1982;16(6):533–549. doi: 10.1007/BF00372022. [DOI] [PubMed] [Google Scholar]
  4. Andrew M. E., Braciale T. J. Antigen-dependent proliferation of cloned continuous lines of H-2-restricted influenza virus-specific cytotoxic T lymphocytes. J Immunol. 1981 Sep;127(3):1201–1204. [PubMed] [Google Scholar]
  5. Arenzana-Seisdedos F., Virelizier J. L., Fiers W. Interferons as macrophage-activating factors. III. Preferential effects of interferon-gamma on the interleukin 1 secretory potential of fresh or aged human monocytes. J Immunol. 1985 Apr;134(4):2444–2448. [PubMed] [Google Scholar]
  6. Austyn J. M., Steinman R. M., Weinstein D. E., Granelli-Piperno A., Palladino M. A. Dendritic cells initiate a two-stage mechanism for T lymphocyte proliferation. J Exp Med. 1983 Apr 1;157(4):1101–1115. doi: 10.1084/jem.157.4.1101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bayne E. K., Rupp E. A., Limjuco G., Chin J., Schmidt J. A. Immunocytochemical detection of interleukin 1 within stimulated human monocytes. J Exp Med. 1986 May 1;163(5):1267–1280. doi: 10.1084/jem.163.5.1267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Boraschi D., Censini S., Tagliabue A. Interferon-gamma reduces macrophage-suppressive activity by inhibiting prostaglandin E2 release and inducing interleukin 1 production. J Immunol. 1984 Aug;133(2):764–768. [PubMed] [Google Scholar]
  9. Corte G., Damiani G., Calabi F., Fabbi M., Bargellesi A. Analysis of HLA-DR polymorphism by two-dimensional peptide mapping. Proc Natl Acad Sci U S A. 1981 Jan;78(1):534–538. doi: 10.1073/pnas.78.1.534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cozzolino F., Torcia M., Castigli E., Selli C., Giordani R., Carossino A. M., Squadrelli M., Cagnoni M., Pistoia V., Ferrarini M. Presence of activated T-cells with a T8+ M1+ Leu 7+ surface phenotype in invaded lymph nodes from patients with solid tumors. J Natl Cancer Inst. 1986 Sep;77(3):637–641. doi: 10.1093/jnci/77.3.637. [DOI] [PubMed] [Google Scholar]
  11. Depper J. M., Leonard W. J., Krönke M., Noguchi P. D., Cunningham R. E., Waldmann T. A., Greene W. C. Regulation of interleukin 2 receptor expression: effects of phorbol diester, phospholipase C, and reexposure to lectin or antigen. J Immunol. 1984 Dec;133(6):3054–3061. [PubMed] [Google Scholar]
  12. Dimitriu-Bona A., Burmester G. R., Waters S. J., Winchester R. J. Human mononuclear phagocyte differentiation antigens. I. Patterns of antigenic expression on the surface of human monocytes and macrophages defined by monoclonal antibodies. J Immunol. 1983 Jan;130(1):145–152. [PubMed] [Google Scholar]
  13. Drebin J. A., Perry L. L., Carter R., Greene M. I. Regulation of the immune response to antigens on the malignant cell surface. Springer Semin Immunopathol. 1982;5(2):175–192. doi: 10.1007/BF00199795. [DOI] [PubMed] [Google Scholar]
  14. Egeland T., Lea T. A rapid rosette technique for quantitation and separation of mononuclear cell subsets using monoclonal antibodies. J Immunol Methods. 1982 Dec 17;55(2):213–219. doi: 10.1016/0022-1759(82)90033-3. [DOI] [PubMed] [Google Scholar]
  15. Ferrarini M., Bargellesi A., Corte G., Viale G., Pernis B. Comparative study of membrane and intracytoplasmic immunoglobulin classes in human lymphoid cells. Ann N Y Acad Sci. 1975 Jun 30;254:243–253. doi: 10.1111/j.1749-6632.1975.tb29174.x. [DOI] [PubMed] [Google Scholar]
  16. Ferrini S., Biassoni R., Moretta A., Bruzzone M., Nicolin A., Moretta L. Clonal analysis of T lymphocytes isolated from ovarian carcinoma ascitic fluid. Phenotypic and functional characterization of T-cell clones capable of lysing autologous carcinoma cells. Int J Cancer. 1985 Sep 15;36(3):337–343. [PubMed] [Google Scholar]
  17. Flood P. M., Kripke M. L., Rowley D. A., Schreiber H. Suppression of tumor rejection by autologous anti-idiotypic immunity. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2209–2213. doi: 10.1073/pnas.77.4.2209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Inaba K., Steinman R. M. Resting and sensitized T lymphocytes exhibit distinct stimulatory (antigen-presenting cell) requirements for growth and lymphokine release. J Exp Med. 1984 Dec 1;160(6):1717–1735. doi: 10.1084/jem.160.6.1717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Johnson W. J., Somers S. D., Adams D. O. Expression and development of macrophage activation for tumor cytotoxicity. Contemp Top Immunobiol. 1984;13:127–146. doi: 10.1007/978-1-4757-1445-6_7. [DOI] [PubMed] [Google Scholar]
  20. Kedar E., Ikejiri B. L., Bonnard G. D., Herberman R. B. A rapid technique for isolation of viable tumor cells from solid tumors: use of the tumor cells for induction and measurement of cell-mediated cytotoxic responses. Eur J Cancer Clin Oncol. 1982 Oct;18(10):991–1000. doi: 10.1016/0277-5379(82)90248-6. [DOI] [PubMed] [Google Scholar]
  21. Landay A., Gartland G. L., Clement L. T. Characterization of a phenotypically distinct subpopulation of Leu-2+ cells that suppresses T cell proliferative responses. J Immunol. 1983 Dec;131(6):2757–2761. [PubMed] [Google Scholar]
  22. Lowenthal J. W., Tougne C., MacDonald H. R., Smith K. A., Nabholz M. Antigenic stimulation regulates the expression of IL 2 receptors in a cytolytic T lymphocyte clone. J Immunol. 1985 Feb;134(2):931–939. [PubMed] [Google Scholar]
  23. Manger B., Weiss A., Weyand C., Goronzy J., Stobo J. D. T cell activation: differences in the signals required for IL 2 production by nonactivated and activated T cells. J Immunol. 1985 Dec;135(6):3669–3673. [PubMed] [Google Scholar]
  24. Meuer S. C., Hussey R. E., Cantrell D. A., Hodgdon J. C., Schlossman S. F., Smith K. A., Reinherz E. L. Triggering of the T3-Ti antigen-receptor complex results in clonal T-cell proliferation through an interleukin 2-dependent autocrine pathway. Proc Natl Acad Sci U S A. 1984 Mar;81(5):1509–1513. doi: 10.1073/pnas.81.5.1509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Meuer S. C., Meyer zum Büschenfelde K. H. T cell receptor triggering induces responsiveness to interleukin 1 and interleukin 2 but does not lead to T cell proliferation. J Immunol. 1986 Jun 1;136(11):4106–4112. [PubMed] [Google Scholar]
  26. Mills C. D., North R. J. Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells. J Exp Med. 1983 May 1;157(5):1448–1460. doi: 10.1084/jem.157.5.1448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Mukherji B., Nashed A. L., Guha A., Ergin M. T. Regulation of cellular immune response against autologous human melanoma. II. Mechanism of induction and specificity of suppression. J Immunol. 1986 Mar 1;136(5):1893–1898. [PubMed] [Google Scholar]
  28. Mukherji B., Wilhelm S. A., Guha A., Ergin M. T. Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response. J Immunol. 1986 Mar 1;136(5):1888–1892. [PubMed] [Google Scholar]
  29. North R. J., Bursuker I. Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J Exp Med. 1984 May 1;159(5):1295–1311. doi: 10.1084/jem.159.5.1295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. North R. J. The murine antitumor immune response and its therapeutic manipulation. Adv Immunol. 1984;35:89–155. doi: 10.1016/s0065-2776(08)60575-1. [DOI] [PubMed] [Google Scholar]
  31. Peri G., Rossi V., Taraboletti G., Erroi A., Mantovani A. Ia antigen expression and IL-1 activity in murine tumour-associated macrophages. Immunology. 1986 Dec;59(4):527–533. [PMC free article] [PubMed] [Google Scholar]
  32. Phillips J. H., Babcock G. F. NKP-15: a monoclonal antibody reactive against purified human natural killer cells and granulocytes. Immunol Lett. 1983 Mar;6(3):143–149. doi: 10.1016/0165-2478(83)90096-2. [DOI] [PubMed] [Google Scholar]
  33. Pistoia V., Cozzolino F., Torcia M., Castigli E., Ferrarini M. Production of B cell growth factor by a Leu-7+, OKM1+ non-T cell with the features of large granular lymphocytes (LGL). J Immunol. 1985 May;134(5):3179–3184. [PubMed] [Google Scholar]
  34. Raulet D. H., Bevan M. J. Helper T cells for cytotoxic T lymphocytes need not be I region restricted. J Exp Med. 1982 Jun 1;155(6):1766–1784. doi: 10.1084/jem.155.6.1766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Reinherz E. L., Schlossman S. F. The differentiation and function of human T lymphocytes. Cell. 1980 Apr;19(4):821–827. doi: 10.1016/0092-8674(80)90072-0. [DOI] [PubMed] [Google Scholar]
  36. Roberts N. J., Jr, Prill A. H., Mann T. N. Interleukin 1 and interleukin 1 inhibitor production by human macrophages exposed to influenza virus or respiratory syncytial virus. Respiratory syncytial virus is a potent inducer of inhibitor activity. J Exp Med. 1986 Mar 1;163(3):511–519. doi: 10.1084/jem.163.3.511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Rosenberg S. Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst. 1985 Oct;75(4):595–603. [PubMed] [Google Scholar]
  38. Sanchez-Madrid F., Nagy J. A., Robbins E., Simon P., Springer T. A. A human leukocyte differentiation antigen family with distinct alpha-subunits and a common beta-subunit: the lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1/Mac-1), and the p150,95 molecule. J Exp Med. 1983 Dec 1;158(6):1785–1803. doi: 10.1084/jem.158.6.1785. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Schreiber H. Idiotype network interactions in tumor immunity. Adv Cancer Res. 1984;41:291–321. doi: 10.1016/s0065-230x(08)60019-6. [DOI] [PubMed] [Google Scholar]
  40. Schwab R., Crow M. K., Russo C., Weksler M. E. Requirements for T cell activation by OKT3 monoclonal antibody: role of modulation of T3 molecules and interleukin 1. J Immunol. 1985 Sep;135(3):1714–1718. [PubMed] [Google Scholar]
  41. Stashenko P., Nadler L. M., Hardy R., Schlossman S. F. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980 Oct;125(4):1678–1685. [PubMed] [Google Scholar]
  42. Tsoukas C. D., Landgraf B., Bentin J., Valentine M., Lotz M., Vaughan J. H., Carson D. A. Activation of resting T lymphocytes by anti-CD3 (T3) antibodies in the absence of monocytes. J Immunol. 1985 Sep;135(3):1719–1723. [PubMed] [Google Scholar]
  43. Uchida A., Micksche M. Autologous mixed lymphocyte reaction in the peripheral blood and pleural effusions of cancer patients. J Clin Invest. 1982 Jul;70(1):98–104. doi: 10.1172/JCI110608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Uchiyama T., Broder S., Waldmann T. A. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol. 1981 Apr;126(4):1393–1397. [PubMed] [Google Scholar]
  45. Williams J. M., Deloria D., Hansen J. A., Dinarello C. A., Loertscher R., Shapiro H. M., Strom T. B. The events of primary T cell activation can be staged by use of Sepharose-bound anti-T3 (64.1) monoclonal antibody and purified interleukin 1. J Immunol. 1985 Oct;135(4):2249–2255. [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES